New Approaches to Cocaine Abuse Medications (A) - 6
Cocaine-Related Disorders, Substance-Related Disorders
About this trial
This is an interventional treatment trial for Cocaine-Related Disorders focused on measuring Desipramine, cocaine, depression
Eligibility Criteria
Inclusion: Meets DSM-IV criteria for current cocaine dependence. Used cocaine at least one day in the past month. Currently meets DSM-IV criteria for Major Depression or Dysthymia. Depressive disorder is either: primary (antedates earliest lifetime substance abuse or persistent during 6 months of abstinence in the past or at least 3 months duration in the current episode Age 18-60. Able to give informed consent and comply with study procedures. Exclusion: Meets DSM-IV criteria for past mania (i.e. bipolar disorder), schizophrenia or any psychotic disorder other than transient psychosis due to drug abuse. History of seizures. History of allergic reaction to desipramine or imipramine. Chronic organic mental disorder. Significant current suicidal risk. Pregnancy, lactation or failure in sexually active female patients to use adequate contraceptive methods. Unstable physical disorders which might make participation hazardous such as hypertension, hepatitis or diabetes. Coronary vascular disease as indicated by history or suspected by abnormal ECG or history or cardiac symptoms. Cardiac conduction system disease as indicated by QRS duration >0.11. Current use of other prescribed psychotropic medications within the last 2 weeks. History of failure to respond to a previous adequate trial of desipramine or another tricyclic antidepressant. Currently meets criteria for another substance dependence disorder (DSM-IV) other than nicotine, marijuana or alcohol.
Sites / Locations
- Research Foundation for Mental Hygiene
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Desipramine
Placebo
Participants were treated with desipramine, up to 300 mg per day. All patients received weekly individual manual-guided relapse prevention therapy.
Participants were treated with matching placebo. All patients received weekly individual manual-guided relapse prevention therapy.